rCFO.next {CFO} | R Documentation |
Determination of the dose level for next cohort in the randomized calibration-free odds (rCFO) design for phase I trials
Description
In the rCFO design for phase I trials, the function is used to determine the dose movement based on the toxicity outcomes of the enrolled cohorts.
Usage
rCFO.next(target, cys, cns, currdose,
prior.para = list(alp.prior = target, bet.prior = 1 - target),
cutoff.eli = 0.95, early.stop = 0.95, seed)
Arguments
target |
the target DLT rate. |
cys |
the cumulative numbers of DLTs observed at the left, current, and right dose levels. |
cns |
the cumulative numbers of patients treated at the left, current, and right dose levels. |
currdose |
the current dose level. |
prior.para |
the prior parameters for a beta distribution, where set as |
cutoff.eli |
the cutoff to eliminate overly toxic doses for safety. We recommend
the default value of |
early.stop |
the threshold value for early stopping. The default value |
seed |
an integer to be set as the seed of the random number generator for reproducible results. The default value is set to |
Details
The original CFO design makes deterministic dose movement by constructing two odds ratios, \pi_L =O_C/ \overline{O}_{L}
and \pi_R =\overline{O}_{C}/ O_R
, and comparing them against thresholds \gamma_L
and \gamma_R
, respectively.
The rCFO design introduces a randomization scheme, normalizes odds ratios, \pi_L
, and \pi_R
into probabilities, and constructs
probabilities for dose escalation, de-escalation, and staying at the same dose.
Value
The rCFO.next()
function returns a list object comprising the following elements:
target: the target DLT rate.
cys: the cumulative counts of DLTs observed at the left, current, and right dose levels.
cns: the cumulative counts of patients treated at the left, current, and right dose levels.
decision: the decision in the CFO design, where
left
,stay
, andright
represent the movement directions, andstop
indicates stopping the experiment.currdose: the current dose level.
nextdose: the recommended dose level for the next cohort.
nextdose = 99
indicates that the trial is terminated due to early stopping.overtox: the situation regarding which positions experience over-toxicity. The dose level indicated by
overtox
and all the dose levels above experience over-toxicity.overtox = NA
signifies that the occurrence of over-toxicity did not happen.toxprob: the expected toxicity probability,
Pr(p_k > \phi | x_k, m_k)
, at the left, current, and right dose levels, wherep_k
,x_k
, andm_k
is the dose-limiting toxicity (DLT) rate, the numbers of observed DLTs, and the numbers of patients at dose levelk
.NA
indicates that there are no patients at the corresponding dose level.
Note
When the current dose level is the lowest or highest (i.e., at the boundary), the parts in cys
and
cns
where there is no data are filled with NA
.
The dose level indicated by overtox
and all the dose levels above experience over-toxicity, and these dose levels will be eliminated.
Author(s)
Jialu Fang, Ninghao Zhang, Wenliang Wang, and Guosheng Yin
References
Jin H, Yin G (2022). CFO: Calibration-free odds design for phase I/II clinical trials. Statistical Methods in Medical Research, 31(6), 1051-1066.
Examples
## determine the dose level for the next cohort of new patients
cys <- c(0, 1, 0); cns <- c(3, 6, 0)
decision <- rCFO.next(target=0.2, cys=cys, cns=cns, currdose=3)
summary(decision)
cys <- c(NA, 3, 0); cns <- c(NA, 3, 0)
decision <- rCFO.next(target=0.2, cys=cys, cns=cns, currdose=1)
summary(decision)
cys <- c(0, 3, NA); cns <- c(3, 3, NA)
decision <- rCFO.next(target=0.2, cys=cys, cns=cns, currdose=7)
summary(decision)